Search clinical trials for: GW642444M

Total 13 results

GlaxoSmithKline

Completed

A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Safety, Blood Levels and Effects of GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects

Asthma

Australia
GlaxoSmithKline

Completed

Phase I Study of GW642444M in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.

Pulmonary Disease, Chronic Obstructive

Czechia
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Asthma

Sweden, Australia, New Zealand
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
GlaxoSmithKline

Completed

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Argentina, Poland, Russian Federation, Belgium, Canada, Chile, France, Germany, Korea, Republic of, Netherlands, Peru, Philippines, South Africa, Sweden, Thailand
GlaxoSmithKline

Completed

Study to Assess GW642444 in Asthma Patients

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand

3

Subscribe